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Abstract Iliac artery and vein homografts are crit-
ical for revascularization in living-donor liver trans-
plantation. Since 2010, National Cardiovascular
Homograft Bank and National University Hospital
have collaborated in the pioneer endeavor of banking
iliac vessel homografts for such surgeries in Singa-
pore. This article aims to demonstrate that the
processing, decontamination and cryopreservation
techniques that our bank follow, help preserve iliac
vessel homografts for a longer duration as compared to
homografts preserved using short-term preservation
techniques. This paper reports the first 4 years of post-
operative outcome for recipients as a preliminary
report for a longer-term outcome study. Criteria for
donor assessment, techniques of iliac vessel homo-
graft recovery, processing, decontamination, cryo-
preservation and storage according to the American
Association of Tissue Banks standards are also
described. From 2010 until 2013, we discovered of
the iliac vessel homografts processed, 17 (94.4 %)
were suitable for clinical use. Nine iliac artery grafts
(64 %) and one iliac vein graft (14 %) were implanted.
Irrespective of vessel type, homografts \90 mm in
length were of little use. Of the nine current iliac vessel
homograft recipients, eight patients (89 %) had living-
donor liver transplantation and one patient (11 %) had
reconstruction of the right internal carotid artery after
resection of an aneurysm. Our preliminary results
supports existing literatures that suggest cryopre-
served iliac vessel homografts can be successfully
used for revascularization in liver transplantation and
reconstruction of carotid artery. Encouraging short-
term post-operative patient outcomes have been
achieved, with no report of adverse event attributed
to implanted homografts. We believe that our pro-
cessing, decontamination and cryopreservation tech-
niques have helped preserve the homografts for longer
duration as compared to homografts preserved using
short-term preservation techniques.
Keywords Liver transplantation  Allografts 
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Introduction
Artery or vein homografts are frequently used for
vascular reconstruction in liver transplantation (Martı´nez
et al. 1999). Recovery of vascular grafts was first
recommended by Starzl et al. as a life-savingmeasure for
an unexpected emergency; it provides additional vessel
length for the recipient during organ transplantation
(Starzl et al. 1979). This recovery is important because
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life-threatening complications that affect the hepatic
artery after transplantation can result in ischemia of the
liver graft, causing graft failure or even patient mortality
(Vivarelli et al. 2004a, b). In most cases, vascular grafts,
such as iliac vessels, are recovered together with the liver
from the same deceased donor and used for the same
recipient. However, iliac artery or vein homografts can
also be used when the liver recipient of a living donor
develops late hepatic artery aneurysm/pseudo-aneurysm
or when autologous vein grafts or deceased organ
donor’s artery/vein homografts are unavailable (Sellers
et al. 2002).
Before banking of cryopreserved iliac vessel
homografts started, liver transplant surgeons relied
on other techniques of vascularization. These included
the use of fresh or short-term preserved iliac vessels
from liver donors (Starzl et al. 1979; Martı´nez et al.
1999; Sellers et al. 2002; Muralidharan et al. 2004),
autologous vein grafts (Hwang et al. 2005), allogeneic
cryopreserved vein grafts such as saphenous veins
(Kuang et al. 1996), and even cryopreserved descend-
ing aortic conduit for one of our liver recipients, who
was diagnosed with liver cirrhosis caused by Budd-
chiari syndrome.
Different methods for the short-term preservation
of vascular homografts have been reported. Short-term
preservation is useful for emergency cases which
require the repair of post-transplant vascular compli-
cations in the recipient. Martinez et al. stored iliac
vessel homografts in Terasaki solution (McCoys
lymphocyte culture medium, bovine fetal serum,
HEPES buffer, gentamicin) at 4 C for 1–26 days
(Martı´nez et al. 1999). Sellers et al. treated the vessels
with RPMI-1640 with L-glutamine containing antibi-
otics (240 ug/mL cefoxitine, 120 ug/mL lincomycin,
50 ug/mL vancomycin and 100 ug/mL polymixin B)
at 4–10 C for 24 h. They were subsequently kept in
fresh RPMI-1640 with 2.05 L-glutamine without anti-
biotics, and stored at 4–10 C for a maximum of
30 days (Sellers et al. 2002). Other studies mentioned
the preservation of fresh iliac arteries using University
of Wisconsin solution at 4 C for\10 days (Shames
et al. 2003; Ma et al. 2011). Alternative preservation
media, such as Celsior solution, Euro-Collins solution
and histidine-tryptophan-ketoglutarate (HTK) solu-
tion have also been reported (Vivarelli et al. 2004a, b).
In addition, a few literatures described the long-term
preservation processes: for instance, Mabrut et al.
decontaminated their iliac vessels with antibiotic
solution containing lincocine (120 ug/mL), mefoxin
(200 ug/mL), colimycin (1,000 IU/mL) and vanco-
mycin (50 ug/mL) (Mabrut et al. 2012). The European
Homograft Bank used a different antibiotic regimen
consisting of vancomycin, lincomycin and polymixin
B, with incubation temperature of 4 C for a duration
of 24 h (Jashari et al. 2013). For both centres,
10–15 % dimethyl sulfoxide (DMSO) was used as a
cryoprotectant, and cryopreservation was achieved
through controlled rate freezing (Mabrut et al. 2012;
Jashari et al. 2013). However, despite the clinical
relevance, a paucity of literature exists regarding the
use of cryopreserved iliac vessels and their clinical
outcome (Kuang et al. 1996; Vivarelli et al. 2004a, b;
Mabrut et al. 2012).
Recognizing the critical importance of iliac vessel
homografts for vascularization of liver recipients in
living-donor transplantation, the National Cardiovas-
cular Homograft Bank (NCHB) and the National
University Centre for Organ Transplantation have
collaborated in the pioneer endeavor of banking iliac
artery and vein homografts for such surgeries in
Singapore since 2010. Apart from liver transplanta-
tion, iliac vessel homograft has also been used by our
hospital for surgical emergencies in life-threatening
conditions.
This article is a description of our routine processes
in recovery, processing, decontamination and cryo-
preservation techniques of iliac artery and vein
homografts in compliance to the American Associa-
tion of Tissue Banks (AATB) standards. A retrospec-
tive review of post-operative outcome for homograft
recipients as a preliminary study of a longer-term
outcome study is also presented.
Materials and methods
Donor assessment
Donors are multi-organ donors aged 12–66 years.
Evaluation of donor suitability is conducted by the
clinical coordinator. This includes performing a
physical assessment of the potential donor, reviewing
medical records and the medical social history ques-
tionnaire. The potential donor is excluded if he/she
had engaged in high-risk social behavior and/or is
suspected or tested positive for transmissible diseases
(AIDS, hepatitis B or C, syphilis, dengue fever, active
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tuberculosis), sepsis, malignancies or autoimmune
diseases.
He/she is also deemed unsuitable if his/her blood is
suspected to be hemodiluted, as this will interfere with
the accuracy of the infectious diseases test results.
Plasma hemodilution can occur either when the
potential donor experiences extensive blood loss or
when he/she receives a transfusion of significant
volumes of whole blood, erythrocytes, colloids and/or
crystalloids prior to cross-clamp. The donor’s blood is
defined as hemodiluted when (1) the total volume of
crystalloids transfused in the previous 1 h and colloids
transfused in the previous 48 h is greater than the
donor’s total plasma volume; or (2) the total volume of
crystalloids transfused in the previous 1 h and the total
volume of colloids and blood products transfused in
the previous 48 h is greater than the donor’s total
blood volume.
Homograft recovery, preservation and storage
Stringent aseptic techniques are upheld during the
tissue recovery and processing procedures to prevent
microbial and fungal contamination of the tissues.
First, iliac artery and/or vein homografts are recovered
by the liver surgeon during multi-organ recovery in the
operating theatre. After retrieval, bench work is
performed immediately. This involves the measure-
ment of vessel length and diameter, and rinsing the
tissues in cold saline (0.1–10 C) to remove any blood
clots. Vessels are also inspected for patency and the
presence of sclerosis or trauma. Vessels which are too
short (\90 mm) or display signs of degenerative,
sclerotic or traumatic abnormalities are discarded. As
the AATB has mandated a standardized evaluation
and classification system for homografts, the vessels’
conditions are evaluated and classified into three
categories: (1) tissue with no visible abnormalities, (2)
tissue with imperfections and (3) non-implantable
tissue. Tissues in the first two categories are deemed
morphologically acceptable upon initial assessment
and are transported in cold HTK solution to the NCHB
laboratory for further processing.
As stipulated by the AATB (2012) requirements, the
total ischaemic time must be less than 48 h (AATB,
13th edition). Processing of tissues is performed in an
ISOClass 5 laminar flowhood located in an ISOClass 7
cleanroom. The laminar flow hood work surface is
sterile and draped according to normal surgical
procedure. Before bio-burden reduction, the iliac vessel
homografts are rinsed in three rounds of saline. They
are then decontaminated using the same antibiotic
regimen that the NCHB adopted for disinfecting
cardiovascular homografts, which uses amikacin
(100 ug/mL) and vancomycin (50 ug/mL) in Medium
199 (M199). The incubation condition is 2–8 C for
24–28 h. After antibiotic disinfection, the vessels are
rinsed in fresh M199 without antibiotics for 12 min to
remove any residual antibiotics that may remain on the
tissues.
Finally, the tissue is packaged individually in a
sterile cryogenic bag that contains the freeze solution
(10 % DMSO in M199). Prior to heat-sealing, air is
removed from the bag to prevent rupture of the bag
during temperature changes while thawing. The sealed
bag is then inserted into a slightly larger cryogenic bag
and heat-sealed, creating a double-layer package for
additional sterility protection of the homografts.
Controlled rate freezing of the processed homograft
is attained by operating a tissue freezing profile using a
controlled rate freezer. The rate of cooling is approx-
imately -1 C per minute. The transfer of the
homograft to a quarantine liquid nitrogen storage tank
takes place when the temperature probe of the freezing
surrogate package reaches -50 C.
Quality control
For the safety of recipients, the results of infectious
disease tests and microbiological cultures of tissue and
solution specimens are evaluated. A donor is deter-
mined to be unsuitable if the results of infectious
disease tests are positive, with the exception of the
venereal disease research laboratory (VDRL) test.
When the VDRL result is reactive, a confirmatory
treponema pallidum hemagglutination or treponema
pallidum particle agglutination test is performed to
exclude active syphilis infection. Although some
banks exclude donors with both previous and active
syphilis due to the potential histological damage
caused to the arteries by the infection, AATB stated
that tissue from a donor reactive of syphilis using U.S.
Food and Drug Administration (FDA)-approved non-
treponemal screening assay may be used for trans-
plantation only if the donor’s blood sample is tested
negative using FDA-approved treponemal-specific
confirmatory assay (AATB, 13th edition). Hence,
due to the severe shortage of homografts, NCHB only
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rejects donors with active syphilis to maximise the
number of implantable tissues.
The testing of total antibodies to hepatitis B core
antigen test (anti-HBc total) is also mandatory. If the
anti-HBc total is positive, an additional test for
hepatitis B surface antibodies (anti-HBs) is performed
to rule out current hepatitis B infection. The accept-
able anti-HBs level is C10 l/mL. In addition, a
dengue polymerase chain reaction test and a Myco-
bacterium tuberculosis culture are also performed for
donors who have suspected infection, due to the
prevalence of these diseases in Southeast Asia.
Microbiological cultures for aerobes, anaerobes
and fungi are performed on tissue and solution
specimens after recovery, post-antibiotic incubation,
and before freezing. Cryopreserved iliac vessel ho-
mografts are stored under quarantine until all of the
infectious disease and microbiological results confirm
their clinical suitability. The NCHB’s quality assur-
ance staff checks and verifies all results and donor
records before submitting them for final review to the
Medical Director. After review, clinically suitable
homografts are transferred to a clinical liquid nitrogen
storage tank and made available for transplantation.
Cryopreserved tissues are stored in liquid nitrogen
vapor for duration of 5 years.
Thawing and implantation
The homograft is shortlisted by the transplant surgeon
based on its length. As homografts are mostly used in
the reconstruction of segments 5 and 8 veins from right
liver graft where patency is required only for about
3 weeks, ABO blood group compatibility is not
mandated.
On the day of transplant, the selected graft is
transported to the operating theatre of the transplant
hospital in a cryoshipper at a temperature below
-135 C. After the transplant surgeon approves the
thawing of homograft, the cryopreserved package
containing the tissue is immersed in saline pre-
warmed to approximately 37–42 C. Saline of higher
temperatures is not used; although rapid thawing of the
homograft package can be achieved, this sudden
temperature difference will increase the risk of
breakage of the homograft package, thereby rendering
the tissue non-sterile and non-implantable. After
complete thawing, a circulating nurse cuts the outer
freezing package. The sterile inner package containing
the homograft is then handled by the scrub nurse.
Subsequently, the homograft is rinsed in three rounds
of lactated Ringers or HTK solution for 5 min each to
remove the antibiotics and DMSO residues. Finally, it
is kept in lactated Ringers or HTK solution in a sterile
closed bottle. If the immediate transplantation is not
achieved, the bottle containing the homograft will be
placed either on a tray of ice or in the 4 C refrigerator.
The final step of quality assurance involves the
testing of post-thaw tissue and solution specimens for
microbiological and fungal cultures. If the post-thaw
result is positive, it will be treated as an adverse event
regardless of the cause of contamination. The trans-
plant surgeon will be notified immediately so that a
prompt follow-up on the recipient and appropriate
medical intervention can be administered.
Ethical consideration
The iliac vessel donors are either tissue pledgers or
donation is consented from the next-of-kin for
deceased donors under the Ministry of Health Singa-
pore’s (MOH) Medical (Therapy, Education and
Research) Act. The MOH’s guidelines on Code of
Ethical Practice in Human Biomedical Research and
Helsinki declaration guidelines were consulted. This
study did not expose the donors or recipients to
additional risk or discomfort because this article is a
description of our routine processes and a retrospec-
tive review of post-operative outcome. Furthermore,
since there was no identification of patients in this
article and patient confidentiality was strictly
observed, hence ethics approval was advised to be
unnecessary by our hospital.
Results
Processing activity outcome
Iliac artery and vein grafts have been recovered from
six anatomical locations: (1) left iliac arteries, (2) right
iliac arteries, (3) common and bilateral iliac arteries,
(4) left iliac veins, (5) right iliac veins, and (6) bilateral
iliac veins. Their lengths ranged from 90 to150 mm;
vessels which do not fulfil the minimum length of
90 mm are of little use to the recipients. To date, all the
17 iliac vessel homografts suitable for clinical use
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have been evaluated and classified to be ‘‘tissue with
no visible abnormalities’’.
The program ceased temporarily in year 2012. As a
result, no homograft recovery or implantation was
facilitated during this period. In 2010, there was an
equal number of iliac artery and vein grafts recovered.
However, owing to the low demand for iliac vein
homografts, the number of vein grafts recovered in year
2013 declined to 17 % of the total iliac grafts recovered.
In contrast, the number of iliac artery homografts
recovered increased. For two donors, a pair of iliac
arteries was procured after the surgeons confirmed that
the donors’ vessels were not required for the liver
recipients. In total, nine iliac artery grafts (64 %) and
one iliac vein graft (14 %) were implanted (Table 1).
A review of infectious disease and microbiological
results revealed that 17 (94.4 %) iliac vessel homo-
grafts processed was suitable for clinical use. The
initial contamination rate of post-recovery homografts
was 27.7 % (5 homografts). 80 % (4 homografts) of
these grafts were successfully decontaminated by the
current antibiotic regimen. A fungusMalassezia furfur
was isolated post-recovery in one iliac vein homograft.
Although it was subsequently tested negative for post-
incubation culture, it was still discarded due to the
pathogenicity of the micro-organism. Other common
bacteria that had been isolated post-recovery included
coagulase-negative Staphylococcus and non-methicil-
lin-resistant Staphylococcus aureus (Table 2). The
former is a common skin commensal, while the latter
is frequently found in the human respiratory tract.
Recipients and outcome
Eight (89 %) iliac vessel homograft recipients were
patients who underwent living-donor liver transplan-
tation. Of these, one recipient received a pair of iliac
artery grafts from the same donor. An elderly patient
who was diagnosed with a right mycotic internal
carotid artery aneurysm also received an iliac vessel
homograft. As a case of surgical emergency, he
urgently required a vessel for reconstruction of the
right internal carotid artery after resection of the
aneurysm (Table 3). All the recipients recovered and
are doing well post-operatively.
Discussion
This collaborative program has seen a higher demand
for iliac artery homografts as compared to iliac vein
homografts. This is because there are more advantages
to using an iliac artery homograft, which includes (1) it
has a thicker wall, and can retain its length, axis and
Table 1 The number of iliac vessel homografts recovered versus the number of homografts implanted each year
Iliac vessel
homograft





















Artery 2 1 (50 %) 4 4 (100 %) 1 1 (100 %) 7 3 (43 %)
Vein 1 0 (0 %) 4 1 (25 %) 0 0 (0 %) 2 0 (0 %)
Table 2 Types of micro-organisms isolated from iliac artery and vein homografts
Total no. of
homografts


















6 1 Malassezia furfur 1 –
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shape after restoration of blood flow in the hepatic
vessels, (2) the probable benefit of decreasing the
incidence of early anastomotic stenosis, (3) the
surgical technique for iliac artery graft is easier than
for iliac vein graft, and (4) its short-term patency rate
was comparable to that of an iliac vein graft (Hwang
et al. 2005). We also learned that irrespective of vessel
type, homografts of a length\90 mm were of little
use. As a result, the homografts of shorter lengths
recovered in 2009 during the initial phase of our
bank’s operation had to be removed from the inven-
tory of transplantable tissues after they had reached the
5-years of maximum cryopreservation shelf-life.
Henceforth, to maximize the probability of graft
utilization, iliac vessel homografts of as great a length
as possible (C100 mm) will be procured.
Not all liver transplant patients require the implan-
tation of an iliac vessel homograft during surgery.
Previously, the absence/thrombosis of the portal vein
in the recipient or abnormal hepatic arteries in the
donor were contraindications to liver transplantation.
However, these problems were overcome by the use of
iliac artery or vein grafts from the donor. This
technique has since become standard procedure
(Strong 2001). It has also been discovered that
recipients who have been on long-term steroid therapy
pre-transplantation are more susceptible to developing
a diseased wall in the hepatic artery. This is a result of
steroid-induced angiopathy related to hypercholerste-
remia and the diabetogenic effect of steroids (Khalaf
et al. 2007). For such recipients, iliac vessel homo-
grafts should always be made available during
surgery. The main advantage of using cryopreserved
homografts is their availability for elective surgeries.
As such, it is especially beneficial for living-donor
liver transplant patients. Unlike cadaveric donor liver
transplant patients who can receive the liver and fresh
iliac vessel from the same deceased donors, living-
donor liver transplant patients have no option of
receiving fresh homografts for revascularization when
artery complications are discovered peri-operatively.
They can only rely on cryopreserved homografts.
Usually, liver transplant surgeons can only ascertain
whether iliac vessel homograft is required after
assessing the condition of the recipient’s vessels
during surgery. Therefore, as a cost-saving measure
for the recipients, our bank is activated for homograft
transportation and thawing only on the day of surgery.
This is usually done after the surgeons determine if
there is a requirement for the reserved homograft.
The significance of ABO blood group incompatibil-
ity as a risk factor that results in early homograft
degeneration has been controversial. Mostly, correla-
tions are postulated from the analysis of post-operative
graft and recipient outcomes. Experiences in organ
allotransplantation have shown that donor-recipient
blood group incompatibility elicits a strong rejection
response. Therefore, blood group cross-matching is
performed in many centers (Kadner et al. 2001). In
contrast, there are centers in which donor-recipient
blood-group matching is considered to be unnecessary
(Hwang et al. 2005; Mabrut et al. 2012). Justification
derived from immunological studies, such as the one
conducted by Kadner et al. who reported that cryopre-
served homografts did not appear to possess an endo-
thelial layer, as observed from a lack of CD31
expression. Moreover, the blood group antigens were
not detected on cryopreserved homografts that had been






1 Iliac artery graft Primary sclerosing cholangitis Living-donor liver transplantation
2 Iliac artery graft Liver cirrhosis secondary to autoimmune hepatitis
3 Iliac artery graft Hepatitis C liver cirrhosis
4 Iliac artery graft Acute liver failure secondary to hepatitis B flare
5 Iliac artery graft Hepatitis C liver cirrhosis
6 Iliac artery graft Cryptogenic liver cirrhosis (possibly NASH-induced)
7 Iliac artery graft Hepatitis B flare
8 Iliac vein graft Cryptogenic liver cirrhosis
9 Iliac artery graft Right mycotic internal carotid artery aneurysm Reconstruction of right internal carotid
artery after resection of aneurysm
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thawed, unlike fresh tissues in which the strong
expression of the antigens was detected (Kadner et al.
2001). In addition, Martinez et al. reported that the
actuarial liver transplant survival rates for recipients of
ABO-incompatible vessels were not statistically differ-
ent from recipients of matched fresh vessels (Martı´nez
et al. 1999). Finally, for organ recipientswho are already
on immunosuppressive therapy, the therapy will abro-
gate their immune response to the donor grafts (Shaddy
and Hawkins 2002). This explains why allografts may
function as well as autografts (Sellers et al. 2002) and
suggests that donor-recipient blood-group matching
might not be required. The implication of removing the
requirement for ABO compatibility between recipient
and donor homografts is an increase in the availability of
cryopreserved homografts for the recipients (Mabrut
et al. 2012).
Despite encouraging short-term results, which
revealed a 100 % survival rate and no cases of graft
failure, infection or adverse events attributed to the
implanted homograft among our recipients, the long-
term post-operative outcome should be further studied.
The long-term outcome appears to vary depending on the
type of complication (thrombosis or stenosis), timing of
the arterial disease (early or late presentationwith respect
to the time of transplantation) (Vivarelli et al. 2004a, b),
the indications for liver transplantation (Khalaf et al.
2007) and the promptness of diagnosis (Vivarelli et al.
2004a, b). The initial technical success rates and long-
term graft survival appear to be promising (Martı´nez
et al. 1999; Del Gaudio et al. 2005; Khalaf et al. 2007;
Jashari et al. 2013). For example, Khalaf et al. reported
that the survival rate of the grafts and patients at 5 years
post-transplantation was approximately 80–90 %, with a
10-year survival rate of approximately 75 % (Khalaf
et al. 2007). Del Gaudio et al. reported that 1-, 3- and
5-year overall survival were approximately 70 % each
(Del Gaudio et al. 2005). Liver recipients for autoim-
mune hepatitis were reported to show exceptionally
encouraging long-term outcomes, with patient and graft
survival at approximately 90 % (Khalaf et al. 2007). In
contrast, Kuang et al. reported that in his institution,
retrospective analysis of long-term cryopreserved iliac
vein graft performance (C3 years) in portal vein recon-
struction in living-donor liver transplantation revealed a
high rate of late graft failures (Kuang et al. 1996). In
addition, Del Gaudio et al. suggested that retransplanta-
tion, donor age and iliac artery conduit were significant
risk factors contributing to poor graft survival and high
incidence of early hepatic artery thrombosis (Del Gaudio
et al. 2005).
In our context, long-term follow-up is challenging.
Firstly, our number of both donors and recipients are
very small, which makes an accurate and representa-
tive study of long-term outcome difficult. Secondly,
some of our foreign recipients are no longer on follow-
up with our hospital after discharge. Thirdly, the
causes of iliac vessel graft failure and patient survival
are multifactorial and difficult to predict due to the
complications of liver transplantation (in particular,
liver rejection and the extent and effects of immuno-
suppression) which might affect the iliac vessels’ graft
performance and outcome (Khalaf et al. 2007).
In conclusion, our preliminary results supports
existing literatures that suggest iliac vessel homo-
grafts, especially the artery grafts, can be successfully
used for arterial revascularization in living-donor liver
transplantation and emergency surgery involving
reconstruction of the right internal carotid artery.
Encouraging short-term post-operative patient and
graft outcomes have been achieved, with no clinically
significant infection or adverse event attributed to the
cryopreserved implanted homograft observed. There-
fore, based on this study of the first 4 years of post-
operative outcome for recipients, although long-term
patency of the homografts remains unknown, we
believe that our processing, decontamination and
cryopreservation techniques help to preserve iliac
vessel homografts for a longer duration as compared to
homografts preserved using short-term preservation
techniques as previously described.
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